News

Press release

Dear Sirs,

We are pleased to inform you that the company Labiana Life Sciences, S.A., has acquired a 100% stake of shares in the company Veterinarski zavod Subotica in the context of its current plan of strategic development

About the company Veterinarski zavod*

Veterinarski zavod Subotica is the company from Republic of Serbia founded in 1921 and it performed its business operations as part of the Patria Group in the former Yugoslavia.

The company deals with production of three basic segments in the domain of health care of animals using its technology:

• Production of vaccines (viral, bacterial and autogenously)
• Production of chemo-pharmaceuticals (sterile injectable solutions that are aseptically filled or finally sterilised, non-sterilised oral solutions and solid pharmaceutical forms) in production areas that were awarded by the EU Certificate of Good Manufacturing Practice (GMP)
• Production of biocides (disinfection and pest control – DDD).

Today the Veterinarski zavod Subotica is active exporting position on the EU market, and recently it has also entered the Russian market, thanks to conformity with ISO standards and HACCP and OMP certificates.

About the company Labiana

Since its foundation in 1958 the company Labiana has achieved a continual development from the manufacture of the food products to modern and competitive company that can offer today various contracts with wide assortment of developmental services and production for some of the most influential companies in Europe. It is also the holder of a marketing authorisation for animal medicines with around 400 licences in more than 50 markets to be exported to Asia, Europe, the Middle East, Africa, and Latin America.

Thanks to this acquisition, the company Labiana shall continue its non-organic growth with special focus on developing markets, the activity the company has started in the first half of 2019 buying majority of shares in Turkish company Zoleant Pharmaceuticals helping its production possibilities in a way that was awarded by the EU Certificate of Good Manufacturing Practice (GMP) in several areas of production.

Labiana on its road of new strategic goals achievement

Having in mind the ambition of the Labiana Company to become significant player in the niche of the animal health care global industry, we consider that this transaction means one more step forward in the framework of our clearly defined plan of strategic development that will help the Labiana Company to achieve its goal, especially in the territory of the East Europe.

This step shall introduce innovations in the fields of research and development, production and marketing of the vaccines and biocides into new lines that are complementary for us in Asia, Europe, Near East, Africa, and Latin America.

This acquisition is also a chance for us to become more influential and reliable regional partner in the Balkans and East Europe in order to support our partners increasing presence on the market, production development, distribution, and licencing.